Announcement no. 12/2007
To OMX Nordic Exchange Hørsholm, Denmark, 15 May 2007
LifeCycle Pharma Receives US Patent for its MeltDose® Technology
Summary: LifeCycle Pharma receives US patent for its MeltDose® Technology
LifeCycle Pharma A/S (OMX:LCP) announced today the issuance of a patent for its
MeltDose® Technology by the US Patent and Trademark Office, US Patent No.
7,217,431.
The patent covers the method of making a particulate material containing a drug
substance with low aqueous solubility, using a unique controlled agglomeration
process.
“The issuance of the first US patent for our MeltDose® technology marks a very
important step in our efforts to protect the company's core technology as well
as to protect all our product candidates which are based upon our MeltDose®
Technology”, said Dr. Flemming Ornskov, President and CEO of LifeCycle Pharma.
“This patent provides broad protection and gives us a potential edge over other
companies competing in the same area” added Dr. Ornskov.
The issue of the MeltDose® patent does not change the company's financial
expectations for 2007.
About MeltDose Technology:
All of LifeCycle Pharma's product candidates are based on MeltDose® technology.
The company's MeltDose® technology has been designed to enhance the release and
absorption of drugs in the body by incorporating the drug in a solubilized form
in a tablet matrix, i.e. as a solid solution. By applying our MeltDose®
technology to create new versions of existing drugs, we believe that products
can be developed significantly faster and cheaper and with a higher success rate
compared with the development required for New Chemical Entities (“NCEs”). This
favourable risk/reward profile is a key component of our business strategy.
For further information please contact:
LifeCycle Pharma A/S
Michael Wolff Jensen
Executive Vice President and CFO
Tel. +45 40 74 62 44
---oo0oo---
About LifeCycle Pharma A/S:
LifeCycle Pharma, headquartered in Hørsholm, Denmark, is an emerging
pharmaceutical company with a broad and late stage product pipeline in
therapeutic areas of cholesterol management, hypertension, organ transplant and
autoimmune diseases. LifeCycle Pharma's product candidates are proprietary and
designed to improve the quality of existing drugs by enhancing the release and
absorption of drugs in the human body. LifeCycle Pharma's proprietary technology
platform, MeltDose® technology, offers lower dosing, reduced side effects and
improved safety and patient compliance, as well as reduced product development
time and development costs. LifeCycle Pharma is listed on the OMX Nordic
Exchange under the trading symbol (LCP). Please visit www.lcpharma.com for
further information about LifeCycle Pharma A/S.
LifeCycle Pharma Receives US Patent for its MeltDose® Technology
| Source: Veloxis Pharmaceuticals A/S
Attachments
